On January 5, 2021 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, reported that a replay of its December 15, 2020 presentation and Q&A session by a panel of investors from the Annual LD Micro Main Event (XIII) is now available (Press release, Greenwich LifeSciences, JAN 5, 2021, View Source [SID1234573461]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the presentation, Snehal Patel, CEO of Greenwich LifeSciences, discusses the Company’s development of GP2, including the recently published Phase IIb trial final efficacy data showing 100% disease free survival or 0% breast cancer recurrences in HER2 positive patients over 5 years of follow-up, an overview of the planned Phase III trial, and upcoming milestones.
To view the replay directly, please click here. To view the replay from the LD Micro main page, please navigate to the Tuesday schedule under Track 2.
About LD Micro
LD Micro is the host of the most influential conferences in the small-cap world. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). With the recent SRAX acquisition, LD has access to the largest active base of microcap investors in the world at over 2 million and counting. For more information, please visit the conference website at: View Source
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.